Revision surgery for loosened hip prostheses is a heavy burden for elderly patients with comorbidity. As an alternative to surgery we performed a study to stabilise the prosthesis by percutaneous cement injection after removing inflammatory tissue with an intra-articular virus-directed enzyme prodrug approach. Twelve elderly patients with debilitating pain from a loosened hip prosthesis were included in a phase 1 doseescalating clinical study. The patients were admitted to the hospital for 10 days for an intra-articular vector and prodrug injection, and subsequently for a percutaneous bone cement injection. This paper reports the adverse and serious adverse events of the study. After prodrug injection 9 of 12 patients had gastrointestinal adverse events (nausea, vomiting, and diarrhoea), and 8 patients had hepatic adverse events (rise in aspartate aminotransferase and alanine aminotransferase). Five patients developed anaemia (World Health Organisation grade 1 or 2) from hematomas after cement injection. There were four serious adverse events in the first 6 months after vector injection, but these were not related to gene therapy as judged by an independent safety committee. There was no dose-limiting toxicity. However, extensive comorbidity in these patients makes it difficult to fully establish the safety of this approach in this small and heterogeneous patient population.
Introduction
A major complication in total hip arthroplasties is loosening of the prosthesis, resulting not only in pain and walking difficulties but also leading to a higher risk for dislocations and pathological fractures. 54 Revision surgery has a high morbidity and mortality rate, especially in elderly patients with comorbidity. At present there are no alternative treatments for prosthesis loosening other than extensive surgical revision of the prosthesis.
Aseptic loosening by particulate-induced osteolysis is the most common cause of implant failure. Wear particles, produced by any artificial joint, such as particles of polyethylene and metal, are phagocytosed by macrophages, leading to secretion of inflammatory cytokines. 43 The resulting chronic inflammation eventually produces interface tissue, a pseudomembrane of synovium-like interface tissue with activated macrophages, fibroblasts, giant cells and osteoclasts.
The prodrug CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] is a weak monofunctional alkylating agent, which is converted by the Escherichia coli enzyme nitroreductase (Ntr) to a cytotoxic derivative. 68 Cells containing Ntr convert CB1954 into a bifunctional alkylating agent that is capable of forming DNA interstrand crosslinks, resulting in apoptosis or cell death. 18, 34, 102 Because there is no human homolog to Ntr 23 , only cells expressing the nitroreductase gene are killed when exposed to CB1954. This makes the Ntr-CB1954 combination exploitable for a virus-directed enzyme prodrug therapy (VDEPT) approach. To this end, CTL102 was constructed, an E1, E3-deleted replication-deficient human adenovirus serotype 5 vector, engineered to contain the E. coli nfsB gene under the control of the immediate-early (IE) promoter of the human cytomegalovirus. 34, 125 In our laboratory, previous experiments have shown the efficacy of the transduction and destruction of synoviocytes and fibroblasts from interface tissue by HAdV-5-Ntr (CTL102) and CB1954. 30 On the basis of promising preclinical findings we performed a phase 1 clinical trial to test the safety and feasibility of an intra-articular VDEPT approach to destroy periprosthetic interface tissue and refix loosened prostheses with percutaneous cement injection into the periprosthetic space. The clinical results of this phase 1 clinical trial were previously published. 28 The study has four potential sources of toxicity: the vector, the prodrug, the vector-prodrug combination, and the percutaneous cement injection. The safety of the prodrug CB1954 in patients was shown by Chung-Faye and coworkers; 23 the safety of the vector CTL102 was shown by Palmer and coworkers. 91 This paper describes the safety of the vector-prodrug combination and the cement injection.
proefschrift.indd 127 27-11-2009 10:59:33
Materials and methods

Trial design
For a description of the trial design, patient selection, preparation and administration of vector and prodrug, and cementing technique (Figure 1 ), the reader is referred to de Poorter et al., 28 where clinical results are shown.
Safety measurements
Safety for the patient was the primary objective in this study. Adverse events reporting is based on the World Health Organisation (WHO, Geneva, Switzerland) recommendations for grading of acute and subacute toxic side effects (World Health Organisation), using a five-point scale (0, within normal limits; 1, minimal; 2, moderate; 3, severe; 4, intolerable). Adverse events are defined as pre-existent (before gene therapy), early (0-7 days after vector administration), intermediate (8-30 days after vector administration), and late (> 30 days after vector administration). Adverse events were recorded up to 6 weeks after vector administration. Vital signs (blood pressure, pulse rate, temperature, and breathing frequency), medical history, and a visual analogue scale (VAS) for pain were measured after vector injection every 30 
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minutes for the first 4 h, then hourly to 8 h after vector injection, and then every 4 h to 24 h. After 24 h these controls were done every 6 h until prodrug injection, and subsequently every day. In addition, vital signs were controlled 30 min and 1, 2, 4, 6, and 12 h after prodrug injection. Blood samples for haematological and biochemical analysis and urine samples were taken 1, 3, 6 and 8 days after vector injection. After discharge from the hospital adverse events were monitored at time points 2, 4, and 6 weeks after vector injection. In some patients who lived far from the hospital these controls were done after 3 and 6 weeks. For each adverse events the following characteristics were recorded: patient number, description of adverse event, WHO grading, date of first occurrence, date of last occurrence, relation with study, outcome of the event, relation with gene therapy, and whether the adverse event required treatment.
Results
Patient characteristics
Twelve patients between 72 and 91 years (mean, 82 years) were treated. Relevant medical histories of the patients are outlined in Table 1 . The dose of CTL102 vector ranged from 3 x 10 9 particles to 1 x 10 11 particles. One patient in the second dose group (1 x 10 10 particles) and one patient in the third dose group (3 x 10 10 particles) actually received a lower vector dose (8.3 x 10 9 and 2.6 x 10 10 particles, respectively) than was planned, because the contents of the syringe could not be injected entirely.
All patients were intended to receive a prodrug dose of 24 mg/m 2 with a maximal concentration of 2mg/ml in the joint space, but after gastrointestinal and hepatic ad- 
Adverse events
Overall there were 100 adverse events observed in the 12 patients (Table 3) . Fifteen adverse events were hematologic, 12 were metabolic, 17 gastro-intestinal, 19 hepatic, 15 renal and 22 were in the category 'other'. There were no adverse events in the coagulation, pulmonary, cardiovascular and neurological categories. The number of adverse events per patient ranged from three for patient 6 to 19 for patient 4. Thirty-two The adverse events reporting is based on the WHO Recommendations for grading of acute and subacute toxic side effects, using a 5-point scale (0 = within normal limits; 1 = minimal; 2 = moderate; 3 = severe; 4 = intolerable). Each adverse event is defined in a footnote. of the findings that had to be marked as adverse event according to the WHO criteria were present during the inclusion procedure, but were not a reason to exclude the patient from the study. Fifty-one adverse events occurred in the first week after vector injection. Seventeen adverse events occurred between the second and sixth weeks. The events are discussed per organ system.
Hematologic adverse events
Four patients had pre-existent anaemia grade 1 (patient 1, Hb 6.7 mmol/litre; patient 3, Hb 6.5 mmol/litre; patient 4, Hb 6.4 mmol/litre; patient 11, Hb 6.3 mmol/litre).
One patient had a low haemoglobin level at hospital admittance, but not during the (patient 11, 3.5 x 10 9 leukocytes/litre 1 day after vector injection, recovering to 4.6 x 10 9 leukocytes/litre 5 days after vector injection; and thrombocytes 99 x 10 9 /litre 1 day after vector injection and still less than 100 x 10 9 /litre at end of follow-up).
Metabolic adverse events
One patient had diabetes mellitus and had grade 1 hyperglycaemia (Patient 8, glucose 1 day after prodrug injection. All metabolic adverse events were asymptomatic.
Gastro-intestinal adverse events
One patient had pre-existent nausea and vomiting. Approximately 6 h after prodrug injection 9 of 12 patients developed nausea and vomiting (Table 4) Three of the first four patients had diarrhoea grade 1 (increase of defecation frequency of two to three times per day) up to 2 weeks after prodrug injection. After the fourth patient the prodrug dose was lowered to 16 mg/m 2 . high AST and ALT at hospital admittance, returning to normal in 1 week, whereas she had normal levels at inclusion. Eight patients had a rise in AST 4 to 6 days after vector injection (2 to 4 days after prodrug injection), and four of these patients also had a rise in ALT. In patients 2 and 3 these were grade 2. Patient 4 had a second rise in AST 30 days after vector injection, and a second rise in ALT with a maximum at 7 weeks follow-up. 
Hepatic adverse events
Other adverse events
All patients had pre-existing pain in the hip (WHO-grade 4; needing pain killers), which was an inclusion criterion. Ten of 12 patients had at any time point a body temperature between 37 and 38°C. One of these patients had a body temperature of 38.1°C 0.5 h after prodrug injection, which is an adverse event grade 2.
Serious adverse events
Four serious adverse events were registered during 6 months follow-up; none was directly related to the VDEPT approach. Patient 1 was diagnosed with uterine carcinoma 8 weeks after vector injection. The patient died of the carcinoma 4 months after vector injection.
Patient 4 was a 91-year old patient with multiple myeloma who died of progressive kidney failure 3 months after vector injection. The exact cause of the kidney failure could not be determined, but it was assumed to have its origin in a kidney localisation of the multiple myeloma. Consent for autopsy was not obtained.
Patient 6 was admitted to the hospital 6 months after vector injection for dehydration and was discharged after a few days.
Patient 8 was admitted to the hospital 3 months after vector injection for hyponatremia and hypotension and was discharged after a few days.
Discussion
In this phase 1 clinical gene therapy study no dose-limiting toxicity occurred. Vector administration could be continued until the proposed highest dose of 1 x 10 11 particles.
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However, prodrug dose was lowered because of inconvenient adverse events in the first four patients (i.e., nausea and vomiting, and hepatic adverse events). At 6 weeks follow-up, 8 of 12 patients had clinical benefit from the gene therapy and cement injection treatment. 28 Harvey et al. 55 summarise experiences on adverse events in local administration of HAdV-5 vectors in 90 individuals. The most common adverse events they reported were transient fever and leucocytosis. In our study on hip prosthesis loosening 10 of 12 patients had grade 1 fever at any time (mostly already at inclusion), and 1 patient had a temperature of 38.1°C (grade 2) 30 min after prodrug injection. Occurrence of fever was not related to the time of vector injection. As temperature exceeding 37°C
were already present mostly at inclusion, and it did not increase much further during the study, it is not likely that it was caused by any of the study products. In a phase 1 study for safety of the CTL102 vector alone, the vector was injected directly into hepatic tumours up to doses of 5 x 10 11 particles (Palmer et al.) 91 and asymptomatic fever (d38.5°C) was seen in 4 of 18 patients 4 to 8 h after vector injection; leukocytosis was not seen in any of the patients. As a joint is a more or less closed compartment, and inclusion of the patients was limited to those who had neutralising antibodies against HAdV-5, thereby inactivating the viral vector outside the joints, exposure of the vector particles to the immunologic system may be minimal, which explains the lack of leukocytosis. Two patients, one in the third and one in the fourth dose group, had leukopenia (grade 1) 1 day after vector injection. This has been described previously in a suicide gene therapy trial, and was explained by bone marrow depression by the prodrug, whereas in our study the leukopenia occurred before the prodrug was injected.
The cause of leukopenia in our study is unknown.
One patient in the highest vector dose group, who already had a platelet count of 112 x 10 9 at inclusion, showed an asymptomatic decrease in platelet level grade 1. This feature of thrombopenia was shown previously in a toxicity-study with baboons, 85 and was also shown in one study with human subjects, 110 and in these studies was attributed to probable cytokine induction.
Besides a rise in creatinine levels no renal adverse events after local vector injection are recorded in the literature. 55 In our study 8 of 12 patients had hematuria or proteinuria. Patient 1 had hematuria at inclusion and developed proteinuria during follow-up.
This patient was diagnosed with uterine carcinoma, which could be an explanation for her hematuria and proteinuria. Patient 4 had pre-existent kidney failure with hematuria, proteinuria and high levels of creatinine. Patient 11 had a catheter à demeure at hospital admittance, which could explain her hematuria and proteinuria. Two patients (patient 5 and 12) developed cystitis during hospital stay, explaining the hematuria and proteinuria. Hematuria among the other three patients might be explained by antico-agulants, which are given to all surgical patients in the department during hospital stay for thrombosis prophylaxis.
Nine of 12 patients experienced nausea and vomiting starting 6 h after prodrug injection, with patient 4 needing parenteral fluid administration because of dehydration.
Nausea and vomiting, and other flulike symptoms, were reported by previous studies as side effects from 110, 113 However, in the present study the nausea and vomiting are more likely to be caused by side effects from the prodrug, as the occurrence decreased after lowering the prodrug dose and did not increase with the 30-fold increase in HAdV-5 vector. Besides nausea and vomiting eight patients had a rise in AST levels, with a maximum 4 days after prodrug injection, and four of these patients also had a rise in ALT levels. These were asymptomatic and completely reversible. Two patients in the high prodrug dose group (and lowest adenoviral vector group) had grade 2 rises in AST and ALT levels, and three had diarrhoea. In the prodrug toxicity study of Chung-Faye et al. 23 these adverse events were also reported. In their study patients received a prodrug dose of 24, 30 or 37.5 mg/m 2 intravenously, without previous vector administration. In the 24 mg/m 2 group three of four patients experienced nausea and vomiting (up to grade 3), but no biochemical liver abnormalities occurred.
In the higher dose groups five of eight patients did have a transaminase elevation, after which the authors concluded that 24 mg/m 2 would be the recommended dose.
One patient received 24 mg/m 2 in a peritoneal injection and experienced grade 1 diarrhoea and grade 1 transaminitis. The pathophysiology of the gastrointestinal adverse events of the prodrug is unknown; two possible explanations are considered. First, the most likely explanation is indirect gastrointestinal epithelial toxicity. Another explanation might be conversion of CB1954 to the activated form by Ntr from E. coli present in colonic flora. This pathophysiologic mechanism is impossible to prove because the activated form of CB1954 is highly reactive and has a halftime (i.e., 18 min) that is too short to be detected. In the study by Chung-Faye et al. 23 less than 5% of the drug was detected in the urine and the drug clearance was 184 to 958 ml/min, indicating that the CB1954 metabolism is predominantly hepatic. The latter underscores that the rise in transaminase levels can be explained by liver cell damage by CB1954 metabolites during drug clearance. Although liver toxicity by CB1954 would be a feasible explanation for the rise in transaminases, previous studies with intravenous HAdV- 91 also showed, throughout the study period, no changes in biochemical estimates of liver function after local injection, giving an additional argument that the transaminitis found in our study is caused by the prodrug rather than the (intra-articularly administered) vector. The dose and delivery routes used in the Palmer study and ours may minimise potential adenovirus-mediated liver toxicity. Patient 4 had a second rise of AST and ALT 1 month after vector injection, most probably due to feeding by stomach tube.
None of the patients had adverse events from the spinal anaesthesia. Besides local pain, the percutaneous cement injection caused hematomas and anaemia in five patients. One patient had a large hematoma and developed a transient rise in alkaline phosphatase levels. These adverse events due to cement injection were inconvenient, but relatively mild compared with local complications in revision surgery. Complications caused by the cement itself are rare, as described in the literature, and are associated mostly with hypotension directly after injection of cement or with fat embolisation. 86, 111 Furthermore, these complications will probably not occur with percutaneous cement injection, in which only small amounts of cement are injected. To our knowledge no hematological or biochemical changes have been reported after cement injection.
Four patients not previously diagnosed with diabetes had grade 1 hyperglycaemia 1 to 3 days after vector-injection and one patient with diabetes had grade 2 hyperglycaemia. Hyperglycaemia has been reported as an adverse event in another suicide gene therapy approach by Freytag et al.. 40 A definite explanation for the hyperglycaemia could not be found, but the authors concluded that it may be related to the fact that many elderly patients are known to be borderline diabetics and/ or experiencing treatment-related stress. 40 All four serious adverse events were reported to the Medical Ethics Review Board and the Central Committee on Research Involving Human Subjects by telephone and in writing within 24 h after the SAE was known to the investigators.
In all cases the study's independent safety committee judged the relationship of the SAE with the study. In all four adverse events the safety committee could not find a causal relation between the gene therapy and the occurrence of the serious adverse event.
In conclusion, an intra-articular VDEPT approach with an adenoviral vector and CB1954 as prodrug and percutaneous transosseous bone cement injection is a viable option in the treatment patients with hip prosthesis loosening. No dose limiting toxicity occurred and all adverse effects could be treated. However, the extensive comorbidity in these patients makes it difficult to fully establish the safety of this approach in this small and heterogeneous patient population.
